Komori
Results4967KOBAYASHI PHARMACEUTICAL CO.,LTD.Materials and Chemicals

Summary of Financial Results for the Third Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)

Cumulative third-quarter sales rose a modest 1.3% year on year, while operating profit fell sharply by 41.2%. Quarterly net income attributable to owners of the parent increased 13.6%, mainly due to gains on the sale of investment securities and other factors.

Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-41.2
%
Wording
Conditional
How definitive the wording is.

Results for this period

Third quarter1 January 2026 to 30 September 2026ConsolidatedJapanese GAAP
Net Sales113,492¥ millionYear on year +1.3%Progress 65.6%
Operating profit6,761¥ millionYear on year -41.2%Progress 54.1%
Ordinary income7,454¥ millionYear on year -42.4%Progress 57.3%
Net income attributable to owners of the parent7,737¥ millionYear on year +13.6%Progress 77.4%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥104.09
Financial position at period-end
Total assets250,406¥ million
of which net assets 210,038 ¥ millionEquity ratio 83.5%vs. prior year-end +7.2pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Segment revenueDomestic Business ¥84,381 million (YoY 0.0%), International Business ¥33,980 million (YoY +8.9%), Other (outside reportable segments) ¥4,792 million (YoY +1.6%)
Segment profitDomestic Business ¥7,657 million (YoY -34.4%), International Business ¥-956 million, Other (outside reportable segments) ¥68 million (YoY -43.3%)
Regional sales¥80,313 million (YoY -1.4%), ¥14,911 million (YoY -3.7%), ¥8,023 million (YoY +31.7%), ¥6,429 million (YoY +13.9%), ¥3,313 million (YoY +14.1%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥173,000 million (YoY +4.4%)
Operating profit¥12,500 million (YoY -16.2%)
Ordinary income¥13,000 million (YoY -23.5%)
Net income¥10,000 million (YoY +173.5%)
Annual Dividend Forecast¥104 → ¥106(+1.9%)
Factors Behind Changes in Business Performance

In the domestic business, 9 new products launched this spring and marketing activities contributed to higher sales, while the limited spread of infectious diseases compared with typical years and adverse weather led to sluggish demand for cold-related products and heat-protection products. In the international business, China and Southeast Asia performed well, while shipments to the United States were temporarily restrained due to a change in the contract manufacturer.

Disclosure regarding the going concern assumption

None

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Material subsequent eventsNone
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥279 million, Gain on sale of investment securities ¥3,744 million, Insurance proceeds received ¥372 million, Other ¥21 million / Extraordinary loss Loss on disposal of non-current assets ¥113 million, Product Recall-Related Losses ¥843 million, Business-site consolidation costs ¥713 million, Other ¥237 million
Depreciation and amortization¥6,225 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End78,050,000
Treasury Shares at Period-End3,711,383
Results for this period
ItemDetails
Fiscal Period ClassificationThird quarter
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 January 2026 to 30 September 2026
Net Sales¥113,492 million (YoY +1.3%)
Operating profit¥6,761 million (YoY -41.2%)
Ordinary income¥7,454 million (YoY -42.4%)
Profit attributable to owners of the parent¥7,737 million (YoY +13.6%)
Net income per share¥104.09
Equity ratioEnd of the current fiscal period 83.5 / End of previous period 76.3
Total assets¥250,406 million
Net assets¥210,038 million
Full-year earnings forecastNet Sales ¥173,000 million (YoY +4.4%) / Operating profit ¥12,500 million (YoY -16.2%) / Ordinary income ¥13,000 million (YoY -23.5%) / Net income ¥10,000 million (YoY +173.5%)
Annual Dividend Forecast¥104 → ¥106(+1.9%)
Segment revenueDomestic Business ¥84,381 million (YoY 0.0%), International Business ¥33,980 million (YoY +8.9%), Other (outside reportable segments) ¥4,792 million (YoY +1.6%)
Segment profitDomestic Business ¥7,657 million (YoY -34.4%), International Business ¥-956 million, Other (outside reportable segments) ¥68 million (YoY -43.3%)
Regional sales¥80,313 million (YoY -1.4%), ¥14,911 million (YoY -3.7%), ¥8,023 million (YoY +31.7%), ¥6,429 million (YoY +13.9%), ¥3,313 million (YoY +14.1%)
Depreciation and amortization¥6,225 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥279 million, Gain on sale of investment securities ¥3,744 million, Insurance proceeds received ¥372 million, Other ¥21 million / Extraordinary loss Loss on disposal of non-current assets ¥113 million, Product Recall-Related Losses ¥843 million, Business-site consolidation costs ¥713 million, Other ¥237 million
Disclosure regarding the going concern assumptionNone
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Material subsequent eventsNone
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End78,050,000
Treasury Shares at Period-End3,711,383
Factors Behind Changes in Business PerformanceIn the domestic business, 9 new products launched this spring and marketing activities contributed to higher sales, while the limited spread of infectious diseases compared with typical years and adverse weather led to sluggish demand for cold-related products and heat-protection products. In the international business, China and Southeast Asia performed well, while shipments to the United States were temporarily restrained due to a change in the contract manufacturer.
Items this document does not state (11)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyOrders received and order backlogImpairment lossChanges in the scope of consolidation

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

New products and marketing activities contributed to higher sales, while the situation in the Middle East, limited infectious disease outbreaks and adverse weather led to sluggish demand for some products. In the international business, sales increased in China and Southeast Asia, but shipments to the United States were temporarily restrained due to a change in the contract manufacturer, while investments and the business environment affected profit.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Third Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated) | KOBAYASHI PHARMACEUTICAL CO.,LTD. (4967) timely disclosure | Komori